All In MedTech

Device Trial Radar · NCT06087718

Feasibility of the Maastro Applicator in Rectal Cancer

Introduction of the Maastro Applicator for Endoluminal Boosting in Rectal Cancer: a Pilot Study

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Aug 27, 2024

Primary completion

Oct 6, 2025

Study completion Oct 6, 2030

Sponsor

Lead sponsor
Maastricht Radiation OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Varian Medical Systems
First posted
Oct 18, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this interventional pilot trial is to confirm that Maastro endoluminal HDR ( High Dose Radiation) contact brachytherapy boosting is feasible and may increase the chance of functional organ sparing of the rectum in patients with rectal cancer. Participants will be treated with chemoradiotherapy and an endoluminal boost with the Maastro applicator.

Conditions

  • Rectal Cancer
  • Feasibility
  • Toxicity
  • Quality of Life
  • Radiation Toxicity
  • Radiation Proctitis
  • Brachytherapy
  • Complete Response

Interventions

  • Maastro applicatorDevice

    The dose profile of the Maastro applicator is similar to the dose profile of a CXRT device. Patients will be stratified based on tumor size. The cut-off is set at the maximum diameter of the treatment surface of the Maastro applicator. The boost consists of 3 fractions with a dose equivalent to 30 Gy per fraction prescribed at the surface of the applicator. The 3 boost fractions will be delivered over a 4-week time period. Patients with a tumor size \< 2.5 cm will receive an upfront boost followed by concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days). Patients with a tumor size ≥ 2.5cm will first undergo concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days) and will afterwards receive the boost.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical feasibility of the Maastro boosting technique.Time frame: During treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Maastro

    Maastricht, Limburg, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.